Complicated Bacterial Peritonitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for complicated bacterial peritonitis. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
4
Active US patents
49/100
Avg vulnerability
—
Annual revenue covered

Originators in Complicated Bacterial Peritonitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fresenius Kabi 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating complicated bacterial peritonitis. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28
1
29
1
30
1
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tygacil
TIGECYCLINE
 Fresenius Kabi 4 49 — 2028-10-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7879828 Tygacil formulation 60 2029-02-05
8975242 Tygacil formulation 55 2028-10-24
8372995 Tygacil formulation 53 2030-10-08
9855335 Tygacil formulation 42 2033-04-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9855335 Tygacil formulation 42 2033-04-07
8372995 Tygacil formulation 53 2030-10-08
8975242 Tygacil formulation 55 2028-10-24
7879828 Tygacil formulation 60 2029-02-05

Related